((自动化翻译由路透提供，请见免责声明 ))
10月14日 - ** 远程保健公司WeightWatchers 和Hims & Hers Health 的股价在盘前交易中分别上涨了3.6%和5.4%。
** 美国食品和药物管理局（FDA）周五表示，将重新考虑禁止制药商销售礼来公司 广受欢迎的减肥药和糖尿病药自制版本的决定
** 针对一个行业组织提起的诉讼，FDA表示，在审查替西帕肽是否短缺的同时，它将允许制药厂继续提供这些药物。
** Tirzepatide 是礼来公司 Mounjaro 和 Zepbound 的活性成分，已于 10 月初从 FDA 的短缺清单中删除。
** 这两家远程保健公司和23 and Me公司 旗下的LemonAid Health公司都提供semaglutide的复方制剂，semaglutide是诺和诺德公司 生产的竞争对手药物Wegovy的活性成分。
** LLY 股价小幅下跌，报 930.86 美元，该股今年迄今已上涨约 60
** 截至上次收盘，WW 下跌了约 81%，而 HIMS 的股价今年以来已上涨了一倍多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.